Real-life inhaled corticosteroid withdrawal in COPD: A subgroup analysis of DACCORD

International Journal of COPD

Volumn 12, Issue , 2017, Pages 487-494

  Vogelmeier, Claus ^a   Worth, Heinrich ^b   Buhl, Roland ^c   Criée, Carl Peter ^d   Lossi, Nadine S ^e   Mailänder, Claudia ^e   Kardos, Peter ^f  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Praxis Drs Bily Kellermann   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Department of Anesthesiolgy and Intensive Care Medicine   (Germany)

^e Novartis Pharma GmbH   (Germany)

^f Group Practice and Allergy   (Germany)

Author keywords

Chronic obstructive pulmonary disease exacerbations; COPD exacerbations; Health related quality of life; Inhaled steroids

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; DRUG COMBINATION;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; SECONDARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONVALESCENCE; DISEASE COURSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GERMANY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTER; RISK FACTOR; TIME FACTOR;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; LUNG; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; REGISTRIES; RISK FACTORS; SECONDARY CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85011949150     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S125616     Document Type: Article

References (21)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: www.goldcopd.org. Published 2016. Accessed July 22, 2016.
2. Glaxo Group Limited. Summary of Product Characteristics: Relvar Ellipta 92 micrograms/22 Micrograms Inhalation Powder, Pre-Dispensed. Brentford, Middlesex, UK; 2013. Available from: http://ec.europa.eu/health/documents/community-register/2013/20131113127002/anx_127002_en.pdf. Accessed October 23, 2016.
3. AstraZeneca UK Limited. Summary of Product Characteristics: Symbicort Turbohaler 200/6 Inhalation Powder. Luton, Bedfordshire, UK: AstraZeneca UK Limited; 2015.
4. Patel J, Mapel DW, Roberts MH, et al. Time to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long-acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) combina­tion therapy. Am J Respir Crit Care Med. 2015;191 suppl:A5774.
5. Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10(1):2207–2217.
6. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–905.
7. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane database Syst Rev. 2012;(7):CD002991.
8. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMI­NATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
9. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
10. Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44:1548–1556.
11. Rossi A, Guerriero M, Corrado A; On behalf of the OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriate­ness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77.
12. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294.
13. Kardos P, Vogelmeier C, Buhl R, Criée C-P, Worth H. The prospective non-interventional DACCORD Study in the National COPD Registry in Germany: design and methods. BMC Pulm Med. 2015;15(1):2.
14. Worth H, Buhl R, Criée CP, Kardos P, Mailänder C, Vogelmeier C. The “real-life” COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64–71.
15. Buhl R, Criée C-P, Kardos P, et al. A year in the life of German patients with COPD: the DACCORD observational study. Int J Chron Obstruct Pulmon Dis. 2016;11(1):1639–1646.
16. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.
17. Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149(2):413–425.
18. Calverley PMA, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstruc­tive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
19. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane database Syst Rev. 2014;(3):CD010844.
20. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
21. Nadeem NJ, Taylor SJC, Eldridge SM. Withdrawal of inhaled corticos­teroids in individuals with COPD –a systematic review and comment on trial methodology. Respir Res. 2011;12:107.